Phage Futures 2020 | Kisaco Research
Translating phage-based applications into clinically and commercially viable therapeutics
Washington D.C., USA
5-6 February, 2020
Download Agenda
The Audience
Register

Why Attend

The inaugural Phage Futures Congress 2019 in Washington D.C was the first of its kind to discuss how to translate phage-based application in to clinically and commercially viable therapeutics.

Join us in 2020 as we once again bring together over 250+ representatives from established biotech companies (from human and animal applications), new adopters, key academic researchers and big pharma. Expect to hear:

  • Developments within phage applications across acute and chronic illnesses
  • Regulatory discussions, including clinical trial landscape updates
  • Understanding of the animal health phage applications can translate into progressing human phage therapy commercialisation

POSTER SUBMISSIONS

Looking to showcase your recent work to the phage therapy community?

Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the evening session after the main conference on day one.

Poster abstract submission deadline is on November 29th, 2019.

Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!

If you have any questions please contact [email protected]m

CLICK HERE TO SUBMIT A POSTER

Past attendees

TESTIMONIALS

Who Will Be There

30%
Biotech
15%
Pharma
30%
Academics
10%
Regulatory & Government Authorities
5%
Clinicians & Physicians
10%
Service Providers

Biotech

Pharma

Academics

Regulatory & Government Authorities

Clinicians & Physicians

Service Providers

Speakers

 

Dr Joe Campbell

Research Resources Project Officer
NIH (NIAID)

I am a program officer in the division of microbiology and infections diseases (DMID) in the National Institute of Allergies and Infectious Diseases (NIAID). My primary role is running the base contract under which our in vitro testing pre-clinical services are conducted (https://www.niaid.nih.gov/research/vitro-assessment-antimicrobial-activi...).

Dr Joe Campbell

Research Resources Project Officer
NIH (NIAID)

Dr Joe Campbell

Research Resources Project Officer
NIH (NIAID)

I am a program officer in the division of microbiology and infections diseases (DMID) in the National Institute of Allergies and Infectious Diseases (NIAID). My primary role is running the base contract under which our in vitro testing pre-clinical services are conducted (https://www.niaid.nih.gov/research/vitro-assessment-antimicrobial-activity-resources). In addition, I am involved in the running of contracts in our pre-clinical models of diseases base contract (https://www.niaid.nih.gov/research/pre-clinical-models-infectious-disease). Finally, I run DMID’s bacteriophage interest group.  The goal of this group is to work with the FDA and other federal agencies to promote the clinical use of bacteriophages.

 

Dr Tobi Nagel

Founder & President
Phages for Global Health

Photo Credit: Mark Warren

Dr Tobi Nagel

Founder & President
Phages for Global Health

Dr Tobi Nagel

Founder & President
Phages for Global Health

Photo Credit: Mark Warren

Phages for Global Health is a nonprofit organization that facilitates the application of phages to combat antimicrobial resistance in developing countries. We accomplish this mission in two general ways: by delivering laboratory training workshops through which we teach scientists in developing countries how to isolate and characterize phages locally; and by partnering with developing world researchers to co-develop phage products for specific applications in their countries. Before founding Phages for Global Health, Tobi had 15 years experience in the pharmaceutical industry where she worked with international teams to co-develop products that have been tested in over 80 clinical trials worldwide.

 

Cara Fiore

Microbiologist
Center for Biologics Evaluation and Research, FDA

Cara Fiore

Microbiologist
Center for Biologics Evaluation and Research, FDA

Cara Fiore

Microbiologist
Center for Biologics Evaluation and Research, FDA
 

Dr. Bob Blasdel

Research Director
Vesale Pharma

I work as the Research Director for Vésale Bioscience where I contribute my ten years’ experience in the phage therapy field as well as my expertise in the biology of phages on a microbiological, molecular, structural, multi‘-omics’, and regulatory level. We work on progressing the personalized model of phage therapy, developing and manufacturing phages as APIs for magistral preparations according to the European model of phage therapy.

Dr. Bob Blasdel

Research Director
Vesale Pharma

Dr. Bob Blasdel

Research Director
Vesale Pharma

I work as the Research Director for Vésale Bioscience where I contribute my ten years’ experience in the phage therapy field as well as my expertise in the biology of phages on a microbiological, molecular, structural, multi‘-omics’, and regulatory level. We work on progressing the personalized model of phage therapy, developing and manufacturing phages as APIs for magistral preparations according to the European model of phage therapy.

I spend a lot of time thinking about what I'm going to eat next, why cows tend to orient themselves on a north/south axis, whether viruses are alive or non-living (or undead!), what it could have really been like to have lived under the laws of Solon, structure/function arguments in biology, and the value that I like to pretend the Oxford comma has for ameliorating run-on sentences.

 

Carl Balibar

Principal Scientist
Merck

Carl Balibar

Principal Scientist
Merck

Carl Balibar

Principal Scientist
Merck
 

Dr Shawna McCallin

PhageForward

Dr Shawna McCallin

PhageForward

Dr Shawna McCallin

PhageForward
 

Assaf Oron

Chief Business Officer
Biomx

Assaf Oron

Chief Business Officer
Biomx

Assaf Oron

Chief Business Officer
Biomx
 

Françoise Aubrit

Head of Process Development
Clean Cells

Françoise Aubrit

Head of Process Development
Clean Cells

Françoise Aubrit

Head of Process Development
Clean Cells
 

Jason Gill

Assistant Professor
Texas A&M

Jason Gill

Assistant Professor
Texas A&M

Jason Gill

Assistant Professor
Texas A&M
 

Saima Aslam

Physician
UCSD

Saima Aslam

Physician
UCSD

Saima Aslam

Physician
UCSD
 

David Pride

Associate Professor of Pathology and Medicine
University of California, San Diago

David Pride’s laboratory focuses on identifying viral members of the human microbiome and in identifying their contributions to human health and disease. He is working on understanding the ecology of viruses and their consequences for our close contacts, characterizing their contributions to community antibiotic resistance, and developing model systems to understand how they respond to perturbations.

David Pride

Associate Professor of Pathology and Medicine
University of California, San Diago

David Pride

Associate Professor of Pathology and Medicine
University of California, San Diago

David Pride’s laboratory focuses on identifying viral members of the human microbiome and in identifying their contributions to human health and disease. He is working on understanding the ecology of viruses and their consequences for our close contacts, characterizing their contributions to community antibiotic resistance, and developing model systems to understand how they respond to perturbations.

 

Frenk Smrekar

CEO
JAFRAL

Frenk Smrekar

CEO
JAFRAL

Frenk Smrekar

CEO
JAFRAL
 

Dr Steven Hagens

Principal Scientist
Micreos

After 22 years working with phages both in academia and industry my role is to act as interface between  Micreos Food Safety B.V. and various stakeholders such as regulatory authorities in various countries, large customers in the food industry, academic partners with whom we collaborate as well as ensuring our intellectual property portfolio is well stocked. In addition I guide and sometimes direct new product development within our own research team.

Dr Steven Hagens

Principal Scientist
Micreos

Dr Steven Hagens

Principal Scientist
Micreos

After 22 years working with phages both in academia and industry my role is to act as interface between  Micreos Food Safety B.V. and various stakeholders such as regulatory authorities in various countries, large customers in the food industry, academic partners with whom we collaborate as well as ensuring our intellectual property portfolio is well stocked. In addition I guide and sometimes direct new product development within our own research team.

 

Dr Magda Barbu

Senior Director, Synthetic Biology
C3J therapeutics

Dr. Magda Barbu, Senior Director of Synthetic Biology, leads engineering efforts for C3J’s pipeline of phage therapeutics programs.  Dr. Barbu is an established scientist with over 15 years of experience working with lytic and lysogenic phage in both industry and academia.  Magda combines her deep expertise in molecular biology, phage biology, bacterial pathogenesis and antimicrobial drug development, to set strategy and deliver key preclinical data essential for advancing the synthetic phage programs from bench to clinic. 

 

Dr Magda Barbu

Senior Director, Synthetic Biology
C3J therapeutics

Dr Magda Barbu

Senior Director, Synthetic Biology
C3J therapeutics

Dr. Magda Barbu, Senior Director of Synthetic Biology, leads engineering efforts for C3J’s pipeline of phage therapeutics programs.  Dr. Barbu is an established scientist with over 15 years of experience working with lytic and lysogenic phage in both industry and academia.  Magda combines her deep expertise in molecular biology, phage biology, bacterial pathogenesis and antimicrobial drug development, to set strategy and deliver key preclinical data essential for advancing the synthetic phage programs from bench to clinic. 

 

Dr. Barbu earned her Ph.D. in Microbiology/Molecular Genetics and Biochemistry from the University of Texas Health Science Center at Houston.  Magda completed her postdoctoral training at the MD Anderson Cancer Center, which included identifying druggable targets for cancer and other diseases using in vivo phage display.  She then worked at Synthetic Genomics, Inc. heading up development of the phage engineering platform and related assets, that were subsequently acquired by C3J Therapeutics. Magda has authored 18 peer-reviewed publications, presented worldwide as an invited speaker and received private and priority government grants for her research in antimicrobial therapeutics and synthetic biology.  She has several patents pending.

 

Dr Carl Merril

CSO and founder
Adaptive Phage Therapeutics

Dr. Merril, a 1962 graduate of Georgetown University Medical School studied phage biology and medical applications for over 5 decades at the NIH. His studies were inspired by participation in the Cold Spring Harbor Phage Biology Course in 1966 and they included: the interactions of phage and mammalian systems, the development of enhanced phage strains for use as antibacterial agents and the development of phage libraries as an aid in searching for phage for the treatment of individual clinical infections.

Dr Carl Merril

CSO and founder
Adaptive Phage Therapeutics

Dr Carl Merril

CSO and founder
Adaptive Phage Therapeutics

Dr. Merril, a 1962 graduate of Georgetown University Medical School studied phage biology and medical applications for over 5 decades at the NIH. His studies were inspired by participation in the Cold Spring Harbor Phage Biology Course in 1966 and they included: the interactions of phage and mammalian systems, the development of enhanced phage strains for use as antibacterial agents and the development of phage libraries as an aid in searching for phage for the treatment of individual clinical infections. An extensive, Phage library along with technologies needed to facilitate their use has recently been developed by the Naval Medical Research, Biological Defense Research Directorate and Infections Disease Departments. This technology has been licensed and a Cooperative Research Agreement has been established with Applied Phage Therapeutics (APT), a company cofounded by Dr. Carl Merril and his son , Gregory Merril, where they serve as the Chief Scientific Officer and Chief Executive Officer, respectively.  The primary goal of APT and the Navy is to further the development and clinical appliations of phage, particularly for serious antibiotic resistant bacterial infections.

 

Matthew Tebeau

Chief Operating Officer
Proteon Pharmaceuticals SA

Matthew Tebeau

Chief Operating Officer
Proteon Pharmaceuticals SA

Matthew Tebeau

Chief Operating Officer
Proteon Pharmaceuticals SA
 

Danish Malik

Senior Lecturer, Chemical Engineering Department
Loughborough University

Danish Malik

Senior Lecturer, Chemical Engineering Department
Loughborough University

Danish Malik

Senior Lecturer, Chemical Engineering Department
Loughborough University
 

Mimi Yen

Founder
PhagePro

Mimi Yen

Founder
PhagePro

Mimi Yen

Founder
PhagePro
 

Dr Biswajit Biswas

Chief, Division of Bacteriophage Science, Biological Defence Research Directorate
US Naval Medical Research Center

Dr Biswajit Biswas

Chief, Division of Bacteriophage Science, Biological Defence Research Directorate
US Naval Medical Research Center

Dr Biswajit Biswas

Chief, Division of Bacteriophage Science, Biological Defence Research Directorate
US Naval Medical Research Center
 

Michele Wales

Principal
Inhouse Patent Counsel LLC

Michele Wales

Principal
Inhouse Patent Counsel LLC

Michele Wales

Principal
Inhouse Patent Counsel LLC
 

Leticia Bentancor

Founder
EMLAB

Leticia Bentancor

Founder
EMLAB

Leticia Bentancor

Founder
EMLAB

Senior Event Partner

Event Partners

Lead Media Partner

The Agenda

Fill in your details to download a copy of  the 2020 Phage Futures Congress agenda to see all topics being covered and why you should attend.

Phage Futures Agenda Front Cover

Agenda launched!

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Venue

Hilton McLean Tysons Corner, 7920 Jones Branch Drive, McLean, VA, 22102-3308

This year The Phage Futures Congress returns to Hilton McLeant Tysons Corner. 

Room rate: $229.00 exclusive of applicable state and local taxes, fees and assessments (double room)

Book now: https://book.passkey.com/go/PhageFuturesCongress

Book by 10 January 2019 to benefit from this exlcusive rate.

After this date rates are subject to availability.

hilton_tysons_mclean.png

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Saturday, November 16, 2019 to Wednesday, December 11, 2019
Early Bird - Academic
$799
Early Bird available through December 11, 2019. Save $200.
Must be a full time academic or healthcare professional
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact [email protected]
Saturday, November 16, 2019 to Wednesday, December 11, 2019
Early Bird - SMALL BIOTECH (under 30 employees)
$1699
Early Bird available through December 11, 2019. Save $200.
Must have an active drug pipeline
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact [email protected]
Saturday, November 16, 2019 to Wednesday, December 11, 2019
Early Bird - Investors, Large Biotech, Multinationals, Service Providers
$2199
Early Bird available through December 11th, 2019. Save $400.
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact [email protected]
Wednesday, October 16, 2019 to Thursday, February 6, 2020
STUDENT OFFER – LIMITED PASSES AVAILABLE
$499
Must provide proof of full time study.
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
Must submit a poster. Poster must be accepted to receive special rate
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.